Sponsored by: Investment Center

Something new in your business?  Click here to submit your business press release

Chamber Corner | Main Street News | Job Hunt | Classifieds | Calendar | Illinois Lottery 

Lilly plans another study for Alzheimer's drug

[December 12, 2012]  INDIANAPOLIS (AP) -- Eli Lilly plans another study of a possible Alzheimer's treatment that showed some potential to help mild cases of the fatal, mind-robbing disease.

The new study will delay a regulatory decision on what could become a breakthrough treatment for a disease that has no cure. The additional research may provide data that supports approval of the drug.

The Indianapolis drugmaker says it will conduct the additional, late-stage study of solanezumab (sol-ah-NAYZ-uh-mab) in patients with mild cases of Alzheimer's, but it hasn't determined details.

In August, Lilly said the potential treatment failed to slow memory decline in two separate studies. But scientists saw a statistically significant slowing when they combined trial data.

Doctors and analysts have said they expected Eli Lilly and Co. to do more research before seeking approval.

[Associated Press]

Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.